Tag: Cancer: Kidney

Trial did not meet primary efficacy end point of disease-free survival in patients with localized RCC at high risk for postnephrectomy relapse

Treatment-free survival more than twice as long for nivolumab plus ipilimumab versus sunitinib for intermediate/poor-risk patients

Rate of disease-free survival at 24 months higher with pembrolizumab versus placebo following nephrectomy

Asymptomatic brain metastases incidentally diagnosed in about 4 percent of patients with mRCC during clinical trial screening

Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC

Progression-free, overall survival significantly longer with combo versus sunitinib for advanced renal cell carcinoma

Progression-free survival longer and response rate greater for cabozantinib versus sunitinib in phase 2 trial in adults with PRCC